OREMAVEN
XMM 7,722.00 -2.63% YTD +5.6% OM ASX 450.55 -2.56% YTD +0.1% OM PRECIOUS 349.20 -2.24% YTD +2.5% OM EX-PREC 418.91 -2.72% YTD -1.1% XAU 4,115.59 +2.31% YTD -4.9% GLD 375.49 +0.81% YTD -5.2% GDX 85.75 +1.37% YTD -0.0% SIL 77.33 -1.00% YTD -7.3% COPX 70.23 -5.81% YTD -1.8% URNM 40.07 -2.79% YTD -27.0%
2026-11-06

← SBM management

Full background report

Andrew Strelein

Managing Director and Chief Executive Officer

Career chronology

Contributions and company outcomes

Simberi expansion and Touquoy restart advanced to FID during CEO tenure

FY2026 · issuer reported · high materiality

FY26 reporting records a US$333m New Simberi expansion FID, early renewal of the mining lease to 2038, Lingbao investment proceeds of A$389m, and Touquoy restart permit approval and FID. Simberi oxide operations returned to profitability, with 48,395 oz produced and H2 production 39% above H1. These are reported company outcomes during Strelein’s CEO tenure; attribution of every milestone is not established.

Attribution: Role overlaps event; causation unproven. Strelein has been CEO since July 2023 and held executive oversight during FY26. His issuer profile directly attributes his role in the earlier Bardoc acquisition and Leonora asset sale, but does not attribute these FY26 milestones individually.

Relevance: Evidence of current project and operating delivery, balanced against later execution milestones and risks in both projects.

FY26 Financial Results and Directors’ and Financial Report (Chairman’s review, operating review and FY26 remuneration report, pp. 4-18); Andrew Strelein profile (Career and transaction profile)

Suitability for the current role

Role fit supported; individual record remains incomplete

Evidence cutoff 2026-10-09 · analyst inference · low materiality

Dated primary company filings and appointment records now support the disclosed role and relevant parts of the person’s professional background. They do not establish a complete career chronology, independently verify every credential, or provide a broad personal performance or adverse-record conclusion.

Attribution: Responsibility not applicable. This is a scoped role-fit assessment, not an attribution of a company outcome.

Relevance: Role alignment matters to execution in the current position, but the reviewed evidence does not establish full delivery or control outcomes.

FY26 Financial Results and Directors and Financial Report (Executive or management profile: Andrew Strelein; current role and available career detail)

Evidence gaps

  • Full dated chronology across previous employers, independent confirmation of education/professional memberships, and targeted regulator/court register searches were not completed; logged open-web searches are not exhaustive clearance checks.

  • Full dated chronology across previous employers, independent confirmation of education/professional memberships, and targeted regulator/court register searches were not completed; logged open-web searches are not exhaustive clearance checks.